๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Ottobock SE & Co. KGaA (ETR:OBCK)
Germany flag Germany ยท Delayed Price ยท Currency is EUR
37.70
-0.45 (-1.18%)
At close: Nov 20, 2026
โ† View all transcripts

Earnings Call: Q3 2026

Nov 12, 2026

Summary

9M organic core revenue grew 6.6%, while underlying EBITDA margin rose 190 bps to 26.1%. Reimbursement delays and regional headwinds temper Q4 expectations; FY 2026 growth is currently expected at 6%-7% within confirmed guidance of 6%-8%.

Jens-Philipp Briemle
Head of Investor Relations, Ottobock

Good afternoon, ladies and gentlemen, and a warm welcome to Ottobock's conference call following the publication of our results for the third quarter and the first nine months of 2026. My name is Jens-Philipp Briemle, and I'm Head of Investor Relations at Ottobock. Today's speakers are Oliver Jakobi, CEO, Chief Sales Officer, and member of the Management Board, and Dr. Arne Kreitz, CFO and member of the Management Board. The call and webcast are being recorded. After the presentation, we will open the line for questions. With that, I hand over to Oliver.

Oliver Jakobi
CEO and Chief Sales Officer, Ottobock

Yeah, thanks, Jens, and also welcome from my side. I would like to walk you through our five highlights of the first nine months. First, we outperformed the market, delivering solid growth against a demanding prior year comparison. At the same time, Q3 was partly below our expectation due to the changed reimbursement environment. Organic core revenue grew by 6.6% in nine months and 6.4% in Q3. The regional trends are more differentiated. EMEA grew by 8.7% and APAC by 8.6%, while the Americas declined by 0.8%. The already known growth pattern continued. B2B grew faster than B2C. Product and components remained our growth engine with 9.1% in nine months and 9.9% in Q3. Patient Care grew by 3.3% in nine months and 1.7% in Q3, below our growth ambition. The underlying core EBITDA margin improved to 26.1% in the first nine months.

That means up 190 basis points year- on- year, and reached 27.7% in Q3, reflecting strong scale effects and operating discipline. We do confirm our 2026 guidance, organic core revenue growth of 6%-8%, and an underlying core EBITDA margin of above 27%. We will continue to outperform the market, yet the reimbursement environment is becoming more challenging. We expect to provide an update with our full-year guidance in March 2027. Arne will take you later through the details. Let's take a closer look to the regions where trends became more differentiated. In the first nine months, EMEA accounted for 74% of our core revenue, the Americas for 19%, and APAC for 7%. EMEA generated an organic core revenue growth of 8% in Q3 and 8.7% in nine months, hereof 3.5% coming from Russia.

Driven by double-digit year-to-date B2B growth of 14.4% and continued contribution from Russia and Ukraine, while momentum in other European markets was softer, where more complex reimbursement processes have lengthened the time required to translate underlying patient demand into revenue. In Germany especially, we see effects ahead of the announced reduction of approximately 3% in German reimbursement rates, effective from 2027. Purchasing and fitting patterns may be influenced by the upcoming changes also in Q4. We aim to partially mitigate these headwinds through pricing initiatives in other markets and favorable product mix. B2C in EMEA grew by 3.1% due to slower reimbursement. Russia accounted for more than 11% of reported group revenue in the first nine months. The Americas declined by 1.8% in Q3 and 0.8% in nine months, reflecting strong prior year comparison.

To put this number into perspective, in the first nine months of 2025, Americas stood at organic growth of 16%. Year-to-date, U.S. B2B performance was driven by customers' inventory adjustments, flat with 0.1%, and softer performance in Canada with the end of The War Amps Program and lower patient volumes, and in Brazil, ahead of the election delaying tenders. Patient Care in Americas continued to deliver positive growth at 3.6% year-to-date. We expect some easing of U.S. customers' destocking, also the timing remains uncertain. APAC accelerated to 17.9% organic core revenue growth in Q3, bringing nine months growth to 8.6%. The improvement was driven by catch-up tender-related revenues following softer second quarter, alongside double-digit B2B growth, high single-digit patient care growth, and strong momentum in Australia and Thailand. With this, I hand over to Arne for the financial update.

Arne Kreitz
CFO, Ottobock

Thank you, Oliver. I will now guide you through the financials in more detail. At a glance, in the first nine months, core revenue rose by 8.1% to EUR 1.252 billion, with organic core revenue growth of 6.6%. In the third quarter, core revenue increased by 9% to EUR 433 million, corresponding to organic growth of 6.4%, and supported by double-digit B2B growth in EMEA and catch-up effects in APAC. Growth continued to be led by products and components. Underlying core EBITDA rose by 16.4% to EUR 327 million in nine months, and by 13.5% to EUR 120 million in Q3. The margin increased by 190 basis points to 26.1% in nine months, and by 110 basis points to 27.7% in Q3. Free cash flow amounted to EUR 151 million, compared with EUR 172 million in the prior year period, mainly reflecting higher income tax payments.

In Q3, free cash flow was broadly stable at EUR 79 million. I will come back to this in a moment. Products and components remains our growth engine. Core revenue reached EUR 709 million, with organic growth of 9.1% in nine months and 9.9% in Q3, above the first half rate of 8.7%, and driven by EMEA and APAC. Growth was supported by continued momentum in prosthetics and neuroprosthetics, particularly in high-tech components such as Kenevo and C-Brace, as well as positive contributions from innovations such as the myoelectric Michelangelo Hand. The stronger B2B mix supported group growth and profitability. Patient Care B2C recorded core revenue of EUR 543 million, with organic growth of 3.3% in nine months and 1.7% in Q3. Growth remained positive, with momentum accelerating in APAC during Q3 at 9.3%, and the acquisition of Blatchford's Patient Care business in Norway contributing to reported revenue growth.

Nevertheless, overall, B2C performance remained below our growth ambition, partly reflecting longer reimbursement approvals in several European countries, especially Germany, France, and Belgium. Improving the growth profile of patient care remains an operational priority, supported by our existing network and the continued integration of recent acquisitions. Oliver has already reported the regional growth drivers, so let me focus on the reported figures. EMEA achieved a core revenue of EUR 924 million, up 11.6% reported and 8.7% organically. B2B continued to grow at a double-digit rate, supported by contributions from Russia and Ukraine. The difference between reported and organic growth mainly reflects the acquisition of Blatchford's patient care business in Norway. The Americas arrived at EUR 243 million, -3 % reported and - 0.8% organically. Revenue was impacted by strong prior year comparisons in the U.S., inventory adjustments at U.S. B2B customers, and negative currency effects from the weaker U.S. dollar.

Patient Care continued to grow by 3.6% organically. APAC achieved EUR 84 million after nine months, up 7.2% reported and 8.6% organically, with a Q3 catch-up driven by double-digit B2B and high single-digit B2C growth that normalized the year-to-date growth after a softer first half. Underlying core EBITDA increased by 16.4% to EUR 327 million, with a margin up 190 basis points to 26.1%. Strong profitability remains an important counterweight to the more mixed revenue development. As in the first half, the improvement was driven by the favorable product mix from stronger B2B growth, scale effects, efficiency improvements, and disciplined cost management, particularly in administrative and operations functions. We continue to see opportunities to capture further operational efficiencies. By segment, the margin developed positively in EMEA at 26.7% after 24.4%, and in the Americas at 24.3% after 23.5%. APAC was at 25.3% after 25.7%.

Underlying net income rose by 16.3% to EUR 138 million, a margin of 10.6%. The earnings momentum at EBITDA level carries through to the bottom line. Below EBITDA, three items are worth mentioning. First, depreciation, excluding impairments, increased in line with business development. Second, interest expenses decreased, reflecting lower average net debt versus the prior year period. Third, the tax rate was lower than in the first nine months of 2025, while absolute income tax expenses increased as a result of the improved profitability. Reported net income was EUR 115 million after EUR 54 million in the first nine months of 2025. The strong increase on the reported EBITDA includes the effect of the IPO cost, which were included in our 2025 exceptional items. Free cash flow amounted to EUR 151 million compared with EUR 173 million in the prior year period, mainly reflecting higher income tax payments and a small working capital increase.

In the third quarter alone, free cash flow was broadly stable at EUR 79 million after EUR 80 million in the previous year. On taxes, as explained in the half-year financials, the prior year period benefited from around EUR 20 million of delayed income tax payments, and in 2026, we have one-off effects of around EUR 10 million, including tax refunds, which we expect to receive in 2027. So the lower reported free cash flow does not reflect a weaker operating performance, and CapEx remains in line with our planning. Net debt stood at EUR 1.076 billion at the end of September compared with EUR 1.125 billion at the end of June and EUR 961 million at the year-end 2025. Last 12-month underlying EBITDA increased to EUR 468 million, and leverage improved quarter on quarter to 2.3x after 2.5x at the end of June and the same level at the year-end 2025.

This is despite two conscious uses of our balance sheet this year, the acquisition of Blatchford's Patient Care business in Norway for around EUR 110 million and the dividend payment of EUR 62.1 million. There is no change in our financial policy. We expect the deleveraging to continue in the fourth quarter, supported by growing EBITDA and our seasonally strong cash. Our leverage guidance remains unchanged below 2x at year-end. With this, I hand back to Oliver for the outlook.

Oliver Jakobi
CEO and Chief Sales Officer, Ottobock

Yeah, thanks. Coming to the guidance. Following our organic growth of 6.6% in the first nine months, we confirm the guidance for 2026 of 6%-8% organic core revenue growth and an underlying core EBITDA margin of above 27%. Net CapEx and capitalized R&D remain at EUR 105 million-EUR 150 million, the cash effective tax rate at around 35%, and our leverage guidance at below 2.0x . We now expect a more moderate seasonal uplift in Q4 as reimbursement and regional market headwinds continue to delay the conversion of underlying demand into revenue. These changed market conditions are expected to continue influencing growth momentum into 2027. A detailed guidance will be provided with the full year 2026 results in March. At the same time, the structural demand drivers remain intact, underpinned by Ottobock's innovation leadership and continued opportunities to capture operational efficiencies.

And with this, we open the Q&A session or

Jens-Philipp Briemle
Head of Investor Relations, Ottobock

Thank you, Oliver. We now start the Q&A session. Operator, please proceed with the Q&A.

Operator

Ladies and gentlemen, we will now begin our Q&A session. If you have a question, we ask that you please use the Raise Hand function at the bottom of your Zoom screen or press star nine if dialed in by phone. When it is your turn, you will receive a prompt. Please unmute or press star six and ask your question. If you want to withdraw your question, please lower your hand using the raise hand function or by pressing star nine. To give everyone an opportunity to participate, please limit yourself to two questions at a time. If you have a further question, please raise your hand again to rejoin the queue. Thank you, and a moment for the first question, please. Our first question comes from Anna Ractliffe with Bank of America. Please unmute your line and ask your question.

Anna Ractliffe
Analyst, Bank of America

Hi. Thank you for taking the question. I wanted to dig in a little bit on the organic growth guidance. I think last quarter you had said there's a good chance you end in the upper half of the range. Should I interpret today's update as that might be more likely the middle of the range? Then I wanted to ask about how the changes in Western Europe impact the midterm guidance. If we come in at 7% for this year, that's the low end of the midterm. I guess what offsets are there that could help drive upside, given the Western European reimbursement will be a headwind? Thanks for taking the questions.

Oliver Jakobi
CEO and Chief Sales Officer, Ottobock

Thank you for the question, Anna. Yeah, given the described headwinds, we are expecting the full year 2026 growth to be between 6% and 7%. That's what we do see today. I mean, we are still evaluating the 2027 and midterm guidance. Yeah, so we might see an impact of probably 1% on the growth rate. This we would provide really, this insight we would provide with the guidance 2027, and then we also would give more insight to the midterm planning.

Anna Ractliffe
Analyst, Bank of America

Great. Thank you. Maybe if I could just follow up on the comment you made about Q4 moderating. Is that across both B2B and B2C? Should we think about Q3 as maybe the low watermark for B2C, or maybe it sounds like it will continue to deteriorate? Just any color there would be helpful on Q4. Thank you.

Oliver Jakobi
CEO and Chief Sales Officer, Ottobock

Yeah, it depends. It's affecting both channels, B2B and B2C. The longer approval time is, of course, a factor which hits at first the B2C, but then also following the B2B business. Therefore, we are expecting in both segments a little bit more moderate growth rates than we have seen in the past.

Operator

Thank you. Our next question comes from Falko Friedrichs from Deutsche Bank. Please unmute your line and ask your question.

Falko Friedrichs
Analyst, Deutsche Bank

Thank you, and good afternoon. My first question is, could you quantify the contribution from Russia to your organic growth in the quarter? Maybe also for Russia and Ukraine combined. Then my second question on the slightly lower outlook for 2026 now, with you just having pointed to the lower half of it. Just trying to understand how these regulatory changes all of a sudden changed that picture so dramatically from the last quarter, where you still pointed to the upper end. Isn't it that there's typically good visibility in the industry and those changes don't come overnight? Or is there something else that's also playing into the slightly more cautious growth this year? Thank you.

Oliver Jakobi
CEO and Chief Sales Officer, Ottobock

Okay. Falko, thanks. I will start maybe answering with the last question. Yes, it is in this consequence, we haven't seen reimbursement changes in, I mean, now more than three decades while I'm in the company. A 3% haircut, what we are now expecting in Germany, a year ago, was not anticipated. So also these long approval times are unusual. We had a price cut in France, in Belgium, which normally never happened before. We have seen in some markets delayed price increases, but we have never seen a price decrease. Therefore, this is something in this consequence, we haven't seen it before. That's maybe to your last question. Regarding your question, Russia contribution, I don't have it on the quarter, but the year-to-date growth rate in EMEA was 8.7%. From this, 3.5% are coming from Russia.

Ukraine, we don't have separated because Ukraine is still a low single-digit sales contribution to the overall sales. That's why we are not pointing it out separately.

Falko Friedrichs
Analyst, Deutsche Bank

Okay, thank you. If I can briefly follow up. We are talking about reimbursement changes in three countries. You are operating in a lot more than that. Is this something that could potentially occur in others as well over the next one to two years, this increasing price pressure?

Oliver Jakobi
CEO and Chief Sales Officer, Ottobock

Sorry, I gave three examples, so we see it in more countries. Also in the U.S., for some products, for example, the very upper end of our portfolio, the Genium X4, it is reimbursed under a so-called miscellaneous code, and miscellaneous means each fitting has to be separately approved. Also there, we see much longer approval times. This comes ahead with a lot of requests, more information, more evidence, so things which were not asked before. That is why at the moment, it takes us a bit longer to fulfill all these requests. But for next year, we do see that we have tools in place to mitigate this. So we have AI tools which are now preparing already all these approval requests for reimbursement, taking into account all questions they are asking, providing the answers so that we are shortened this time for next year already.

Then we are working through this new framework, which is given by the reimbursement systems.

Operator

Thank you. Our next question comes from Graham Doyle with UBS. Please unmute your line and ask your question.

Graham Doyle
Analyst, UBS

Yeah. Afternoon, guys. Hopefully you can hear me. Just on this pricing piece, it sounds like this has happened in the last two, three months across quite a few countries. Is that normal where you get these updates around this time of the year? Just to understand that and why it has happened so quickly. If it has happened across quite a few countries, what do you think has changed? What is different in your conversations now versus any point in the last 10, 15 years? Just to understand how sticky this sort of pressure is, because if we are talking like 3% price headwind across the piece, that is a meaningful dent across growth.

Oliver Jakobi
CEO and Chief Sales Officer, Ottobock

Yeah. Thanks, Graham. Yeah. It is a normal timing. Yeah. So, especially when all the reimbursement systems, they also start their budgeting processes, and so they have to see what is happening with the money. What has changed is, I think, really the financial situation of a lot of reimbursement systems. This open discussion now in some Western European countries was never so evident like this year. That was very strange. While we always had in the U.S. a more open conversation with the reimbursement, and it was clear what they are looking for, it was easy to fulfill. Now they are also starting to look around. A lot of patients, they are getting new insurance plans with different deductibles. Yeah. In the U.S., until you are reaching this threshold of deductibles, you have to pay 20% out of your pocket for treatments.

In the past, this threshold was much lower than it is now. Patients are waiting longer because they do not want to pay 20% for a prosthetic or orthotic fitting out of their pocket. That is delaying the situation. But the speed with how fast insurance companies are signing new plans, this is new. That is something what was not there in the last 10, 15, 20 years.

Graham Doyle
Analyst, UBS

Okay. Well, maybe you can unpack that a bit more. What I am trying to understand is how surprising and shocking is this to you, and what is the recourse, and what can you do to push back? If you think back to the financial crisis and the immediate period post that, there was a lot of pressure on healthcare systems in Europe, and across MedTech, we saw a big shift in how pricing started to work. This, as you have given your track record, this sounds materially worse in terms of what is happening with price, but it does not strike me as a bit It strikes me as a more benign backdrop to that. What do you think has caused this sort of cascade of pricing shifts across so many countries at once versus, like, a year ago, were you getting 2%, 3% price uplifts?

Oliver Jakobi
CEO and Chief Sales Officer, Ottobock

Yes.

Arne Kreitz
CFO, Ottobock

Yeah, I think, maybe from my side, you know the typical seasonality that we have, so that we are, you know, having a slower start in Q1 and Q2, and then we typically see the acceleration coming in Q3 and Q4. And what we simply realized now in Q3 is that, you know, this acceleration is more moderate. And I think that's also why Oliver is pointing towards the fourth quarter, that we're expecting to see the acceleration more moderately. And when we're also having our discussions with the countries, why the uplift is more moderate, and we're simply hearing very consistently that the discussions with the reimbursement system and the approval times are significantly longer. I give you an example in France. In France, we have reached the C-Brace reimbursement, and we see a strong pipeline of patients.

So it's not a lack of patients, you know, waiting for the fitting, but the approval timelines, so the argumentation that you need to bring up so that you can effectively convert the demand into revenue, or the, yeah, the patient volume into revenue, is significantly longer than what we've been seeing. Or in Germany, for example, we have the impression that, you know, there's also partly delays moving things into next year, as prices will be lower next year. So, it's a bit of a surprise. We have to say we haven't anticipated that also in our half-year financials, where in Q2 we've been seeing reasonable growth of 8%. But we have to say that the pickup, the typical seasonality that we're seeing, is much more moderate at the moment than what we've been seeing in the past.

Operator

Thank you. Our next question comes from Richard Felton with Goldman Sachs. Please unmute your line and ask your question. Richard, your line is unmuted. Please unmute your end and ask your question.

Richard Felton
Analyst, Goldman Sachs

There we go. I got it. Hi, guys. Yeah, two questions from me, please. First one is a follow-up on the reimbursement topic. Could you maybe help us understand, like, the reimbursement pressures that you're talking about, was that already sort of, like, very much impacting your numbers in Q3, and you have grown 6.5% in spite of those pressures? Or is the stuff you're flagging today kind of incremental and forward-looking, so that becomes a bigger headwind into Q4 and into FY 2027. That's the first one. Then second one, bit more of a technical one on tax rates. So, I saw on your slide, you're expecting effective cash tax rate at 35% this year. I think sort of thinking back to some of the medium-term guidance last year, I think you're expecting a number in the low 20s.

Is that low 20s still the right way to think about the effective cash tax rate going forward, or has that changed as well? Thank you.

Oliver Jakobi
CEO and Chief Sales Officer, Ottobock

Thanks, Richard. I take the first part on the second. Yes, we have seen already these headwinds in Q3, so that is why in Patient Care, we have seen, and that is why I said in the beginning, the 3.5% in Patient care growth was below our expectations. So there where we see it directly, and then we also see it a little bit already in the B2B business, but less. But looking forward, we will see it in both in the same way. Tax rate?

Arne Kreitz
CFO, Ottobock

On the tax rate, yes. This year, I would say it is a little bit exceptional in terms of, as I elaborated, there is a EUR 20 million of delayed tax payments from last year falling into this year. I think I elaborated on that one already at the half-year financials. And we have a second special effect that there is a EUR 10 million tax item where we will be getting a refunding from the tax authorities, but the refunding likely is only happening next year. That is why if I am looking into this year, I see a negative impact of around EUR 30 million. That is why the effective tax rate for this year is elevated. But that should not change our general view and guidance that we have been given on the tax rate, that we still have reasonable tax assets, which we will leverage in the next years ahead of us.

The 25% effective tax rate should still be the guiding point for the next years to come.

Operator

Thank you. Our next question comes from Hugo Solvet with BNP Paribas. Please unmute your line or press star six on your telephone keypad to unmute and ask your question. Hugo, your line is unmuted. Please unmute your end or press star six on your telephone keypad to unmute and ask your question. We will circle back to Hugo. Our next question comes from Oliver Reinberg with Kepler Cheuvreux. Please unmute your line and ask your question.

Oliver Reinberg
Analyst, Kepler Cheuvreux

Oh, yeah. Hi, good afternoon. Also two questions from my side. Firstly, it appears that there's quite a kind of change now in the kind of overall market outlook compared to just a quarter ago. Is this really all reimbursement, or is there any kind of other pressure points you see? Overall, DTC space fighting back, there's more consolidation, which makes pricing in general more difficult. Also, can you just say, like, of this reimbursement impact, which I guess is mostly on B2C, how much of that is there kind of throwback on the B2B business? That would be question number one. Secondly, I think given the share price reduction, it would be great to at least get the numbers now in the kind of right place. Appreciate the color that we talked about, the 1 percentage point probably revision of the outlook from here.

I assume that this refers to the kind of midterm outlook. Is that a kind of fair assumption? On 2027, even if you can't guide yet, I mean, if the revised midterm guidance would be 6%-8%, do you believe that 2027 will also be in this range, and can you already commit to any kind of margin progress next year? I guess any kind of color here would be very helpful. Thank you.

Oliver Jakobi
CEO and Chief Sales Officer, Ottobock

Okay. Yeah, thanks. So, yeah, no, it's not only reimbursement. You're absolutely right. But the questions were around reimbursement, and probably also during our presentation, we referred quite often to the reimbursement. In the U.S., for example, we have seen also this destocking of customers. The root cause is also the reimbursement. It takes much longer for them to get money. The payment terms from the reimbursement side became worse, so they tried to save cash, and so took at first whatever was on stock. Therefore, that's something what we have seen as well. I would not say that we have other significant market impacts. We do not have an extraordinary change in competition or whatever. The consolidation in the B2C sector, yes, it leads maybe to different conditions, but it doesn't change our growth and structural approach.

Therefore, no, it is actually more this, yeah, more economical approach of consolidated customers, destocking, and yeah, and the longer reimbursement approval times. It is not that we face besides France and Belgium, that we are facing really margin decreases for the B2C business. It is more this, the patient. To convert an incoming patient to revenue takes now instead of, let us say, one month, it takes now three months. That means the WIP in most of the patient care clinics is growing. It is not that they have less patients. They only have more WIP because they have to wait for the approvals and then also for the payment. That was the first part. The second part

Arne Kreitz
CFO, Ottobock

I think was on the 1% and the potential influence on 2027 guidance and midterm. Although we need to assess the situation further, what we are seeing from the revenue, from the reimbursement side, as Oliver said, we are expecting around 1 percentage point impact on the top line growth, but we are not setting a guidance today, and we are not talking about the midterm guidance for that. We need to weigh in all factors, also how innovations that we brought to market are now catching up. I think at the beginning of the year in March, when we give our full year results, we can talk about this in more detail. But now with the trend that we are seeing on the reimbursement side, we at least wanted to give you a bit of a tangible data point.

Operator

Thank you. Our next question comes from Beatrice Fairbairn with Berenberg. Please unmute your line and ask your question.

Beatrice Fairbairn
Analyst, Berenberg

Hi. Thank you for taking my questions. A couple from me, if that is okay. On the longer reimbursement approval times, can I clarify whether this is impacting all product sub-segments, or is there a particular one that has been impacted more, whether that is the lower end of product segments or the higher end? Then just on the APAC growth in Q3, would you be able to split out how much the growth was from the tender catch-up after Q2 versus the kind of underlying business growth? Thank you.

Oliver Jakobi
CEO and Chief Sales Officer, Ottobock

Yes, thanks for the question. Yes, you are right. Of course, the longer approval times are playing more in the area of the high-value fittings. That is where we are having our exposure mostly. Therefore, this takes longer. In general, it takes all longer, but especially the reimbursement or insurance companies are taking more time in approving the high-value fittings. Regarding the tender in APAC

Arne Kreitz
CFO, Ottobock

I think it was the expected catch-up. I think in H2, we had very slow growth in the second quarter, and what we said is, there had been a delay on the tender, and in relation to the smaller overall sales that we have in APAC, that can have a relative impact on the quarter. Now what we have been seeing in Q3 is exactly the catch-up. If you are looking now into the year-to-date growth, I think then you are seeing a healthy picture. From that end, it is the expected development that we had communicated also in H2.

Operator

Thank you. Our next question. Apologies.

Oliver Jakobi
CEO and Chief Sales Officer, Ottobock

Sorry. No, APAC generally, yeah, because it is a smaller volume and this kind of tender, then they have a bigger impact than they would have in EMEA or in the Americas.

Operator

Thank you. Our next question comes from Hugo Solvet with BNP Paribas. Please unmute your line and ask your question. Hugo, you are unmuted our end. Please unmute your line and ask your question. We will circle back to Hugo. Our next question comes from Graham Doyle with UBS. Please unmute your line and ask your question.

Graham Doyle
Analyst, UBS

Hey. Thanks again for taking the question. It's just a follow-up. Just for clarity, if there's a 2%, 3% price decrease, right, that's the sort of level we're talking about. You know, we think back to the IPO, we're all building 2%, 3% price increase on a like-for-like basis into the model. That feels like a big swing. Could you just let me know where I'm wrong on that? Because that wouldn't result in a 1% headwind to your midterm guidance. It would be more, which I'm sure as you said, it's not. So if you could just help us piece that together. Yeah, that would be super helpful.

Arne Kreitz
CFO, Ottobock

Yeah. So first of all, I mean, we're now talking about Germany, and next year, where we know that there's a 3% reduction across the board, so to say, which is also new. In the past, it has been more differentiated. This is now 3% by price decrease for the German market. And those price settings, they are, in the first instance, they are impacting the B2C business, the patient care business. On the B2B side, we're always able to better mitigate, because here we are in the end setting the prices towards the patient care business. Won't there be an impact at all? Probably there will be, but not to the same extent. So from that end, I think you need to not apply it now across the board to the global revenues.

This is now a topic more specific to the German market and some influencing factors also, as Oliver explained, in some other markets. That's why we felt it's good to give you our assessment, what impact is resulting out of that, and that is the 1 percentage point of a reduced growth that we're going to see out of that.

Graham Doyle
Analyst, UBS

It would be really helpful. It would be really helpful for us to get that. I think I am getting questions here from investors, and they are not sure if we are saying pricing has totally flipped and is bad, i.e., negative, versus what we thought originally was positive for the last 20, 30 years, or it is just Germany and there are some delays elsewhere. You have listed U.S., Germany, Netherlands, sorry, Benelux, and France. In those countries, could you just tell us what is happening between either a price decline, a delay, just so we understand the different parts, so we understand whether there has been something structural globally or it is just literally pockets of different things happening?

Oliver Jakobi
CEO and Chief Sales Officer, Ottobock

In Germany, it is a 3% haircut, yeah-

Graham Doyle
Analyst, UBS

Yeah.

Oliver Jakobi
CEO and Chief Sales Officer, Ottobock

-on our German Patient Care business directly. But it does not mean that that is a 3% sales and margin decrease, yeah? It will lead into a lower or a different service offering also, yeah? That is not only components for the patient care, but it is also the service they are offering. This will be different. In France, we had for, in our case, one single product, we had a price decrease for the C-Leg. In Belgium, they lowered the expenditure, not saying we are cutting all costs by X%. They only said, "The budget which is available will be cut by a certain percentage." Here, we do have still the opportunity to have the same volume, but it becomes a little bit more difficult to fight for the portion of the cake, yeah? Because the overall volume became smaller.

In the U.S., it is just this lengthy reimbursement scheme, but this is also in all Western European countries a pattern what we see. Reimbursements are asking for more evidence. They are asking much more questions, yeah? It is a tactic, yeah? They are creating now more and more questions. As I mentioned before, our countermeasures, we have an ambient listening tool which we are using in all our patient care centers, and also our customers are going to use it next year, where we are addressing already in the patient assessment all these questions which are asked. We are creating the answers, so this long approval period should reduce during the course of the next year.

Operator

Thank you. Our next question comes from Hugo Solvet with BNP Paribas. Please unmute your line and ask your question.

Hugo Solvet
Analyst, BNP Paribas

Hey, guys. Can you hear me now?

Arne Kreitz
CFO, Ottobock

Yes.

Hugo Solvet
Analyst, BNP Paribas

Cool. Sorry for that. This is Hugo. Just follow up on Graham's question, just not on the top line maybe, but to what extent the price pressure or the lack of price increases can drop through to the margin. You mentioned your ability to potentially tap into efficiencies. To what extent those would be sustainable, and I guess in the context of the long-term guide, what's your ability to deliver the 30% margin also? And just on LATAM, Q3 was impacted by what it seems to be temporary issue. Maybe you can help us and comment a bit on whether you've seen a normalization in the first weeks of Q4. Thank you.

Arne Kreitz
CFO, Ottobock

Yeah, on the bottom line impact, so margin impact, I'd say, all the delaying elements that we're seeing at the moment is less of a margin topic, yeah? I mean, if you're looking into the drivers of our margin, also the margin improvements in the last years, it has always been the three elements of mix effects, scale effects, and efficiencies that we're gaining. If the top line is a bit reduced, then that might have an impact on the scaling effect. But nevertheless, I assume that the mix and the efficiencies that we're gaining is also intact in the next years ahead of us. So, we need to see how now the Q4 is playing out, and then we'll give you an update. We're not expecting a margin decline. Maybe we're expecting a more moderate improvement in the next year to come.

The underlying drivers of our margin improvement, so the mix effects and the efficiency gains, they will also remain intact ahead of us.

Oliver Jakobi
CEO and Chief Sales Officer, Ottobock

Then on LATAM. Regarding Brazil, so these deferred tenders, we do not expect them in because tenders, it's a lengthy process. We do not expect them coming in Q4. We do expect them coming in 2027.

Hugo Solvet
Analyst, BNP Paribas

Okay, thank you. Just a quick clarification to make sure I got this right, but in terms of the reimbursement pressures, in which countries exactly they have kicked in yet, and when all of the reimbursement pressure will have kicked in? Is it like with the 1st of January 2027 when legislations are passed into law, or will it be more gradual through 2027?

Oliver Jakobi
CEO and Chief Sales Officer, Ottobock

I hope I got it right. So which countries? Western European countries, we do have-

Hugo Solvet
Analyst, BNP Paribas

Yes, correct.

Oliver Jakobi
CEO and Chief Sales Officer, Ottobock

Yeah, we do see the pressure. The countries I mentioned before, it is Germany, France, Belgium, less in Italy. Scandinavia, we always have this tender situation, so it is a constant situation there. We have it less in U.K. and Ireland. We also have it now less in Netherlands. But where we are in Western Europe, where we have the biggest stake, France, Belgium, Germany, we definitely see this lengthy approval process. Regarding the price impact, it is Germany from January 2027, but Belgium and especially France, we had already this year.

Operator

Thank you. As a reminder, if you would like to ask a question, please use the raise hand feature. When your name is announced, please unmute and ask your question. Our next question is from Falko Friedrichs from Deutsche Bank. Please unmute your line and ask your question.

Falko Friedrichs
Analyst, Deutsche Bank

Thank you. I would have another clarification question as well. It is on Russia. On my numbers and based on the answer you gave me to my earlier question, Russia was about 2.5% of your growth in the first nine months. Is that correct?

Arne Kreitz
CFO, Ottobock

If you look into our growth in EMEA-

Falko Friedrichs
Analyst, Deutsche Bank

Excluding Russia, this year you are growing 4%. Is that correct?

Arne Kreitz
CFO, Ottobock

We have, I think the number that Oliver provided was, if you are looking into the EMEA number, then we have been growing year- to- date at 8.7%, and the Russia contribution has been 3.5% on that. If you exclude Russia, then EMEA has been growing by 5.2%.

Falko Friedrichs
Analyst, Deutsche Bank

Yeah. Okay, but then on a group level, that should be about 2%-3% from Russia then?

Arne Kreitz
CFO, Ottobock

Should be.

Falko Friedrichs
Analyst, Deutsche Bank

And, right?

Arne Kreitz
CFO, Ottobock

Exactly. On the group level, it's from -

Falko Friedrichs
Analyst, Deutsche Bank

So 4%.

Arne Kreitz
CFO, Ottobock

Yeah.

Falko Friedrichs
Analyst, Deutsche Bank

Yeah. And clarification on that, because if I remember it correctly, the 7%-9%

Oliver Jakobi
CEO and Chief Sales Officer, Ottobock

Sorry, Falko. To exclude Russia is I mean, we had always Russia in our business, yeah? The last 30 years, and Russia was always growing double digit, yeah? Just to delete it would mean you also would delete the whole structure, yeah? Which is also not realistic.

Falko Friedrichs
Analyst, Deutsche Bank

Yeah, I completely understand that. It is just where I wanted to get at is that, if I remember it correctly, the 7%-9% mid-term guidance, right? That is excluding these spike events, right? The word you used to use. Should we think of that medium-term guidance going forward now, whether it is going to be 1% lower as you indicated, or whatever you are going to come up with, as including that as a whole package going forward and not as an addition to it?

Oliver Jakobi
CEO and Chief Sales Officer, Ottobock

Regarding spike events, because we will not talk anymore about spike events because especially this Ukraine-Russia war is now going into the fifth year. It is not a spike event, yeah? What we do see this year already are refittings of those wounded people from the first year. They are most of the time not refitted within the military structure. They are refitted within the civilian structure. This patient base in both countries is just now on another level. Therefore, it is a normal business, yeah? That is why we do not talk anymore about this spike event. For the guidance for 2027 and also for the mid-term guidance next year, you will not get a separate number for spike events because the spike impact is now already relatively low. It does not make sense anymore to set a separate number.

Operator

Thank you. Our last question comes from Hugo Solvet from BNP Paribas. Please unmute your line and ask your question.

Hugo Solvet
Analyst, BNP Paribas

Hey, guys. Just a quick follow-up on the 4% ex-Russia for EMEA. Is that you think a good starting point for next year, or given some of the reimbursement pressures have not yet materialized, trough is probably in Q4 or Q1 2027? Just want to know where exactly we are in that decelerating underlying growth for EMEA. Thank you.

Arne Kreitz
CFO, Ottobock

No, I think what you are seeing already this year, and also in the Q3 numbers, is both the impact on the B2B and B2C side. So that's why we, I mean, consciously are providing the Russian numbers so that you can see there's already impact in the EMEA business also without Russia. From that end, there's a small delay between B2C and B2B, but I think you can see it already in the numbers. So if you're interpreting the numbers, then I'd say that EMEA, specifically Western Europe, has already been comparably slow in Q3, while something was kind of compensated by the continued growth that we're seeing on the Russian side. From that end, we wanted to consciously provide that transparency so that you can see that the Q3 numbers have been kind of exceptionally low. Now, are we expecting that this is continuing?

I'd say, as Oliver said, we are expecting more moderate growth moving into Q4. But all in all, we need to now also better understand how those trends are developing. Again, we will give you an update with the full-year results.

Operator

This concludes the Q&A session. I will now hand back to Oliver Jakobi, CEO, for closing remarks.

Oliver Jakobi
CEO and Chief Sales Officer, Ottobock

Yeah. Thanks a lot for your interest and for your questions. I mean, we delivered and continued our growth trajectory, and I think we also could show that we significantly improved our profitability in the first nine months, and we are confirming the guidance for 2026. So while expecting less pronounced seasonal uplift in the fourth quarter, I mean, we remain focused on disciplined execution, rolling out our innovations next year, integrating our acquisitions, completing the Human Mobility divestment, and capturing further operational efficiencies. We look forward speaking with many of you at our upcoming conferences and roadshows in Paris, London, Frankfurt, and the U.S. So, hope to see you there. Thanks a lot.

Operator

This concludes today's call. Thank you, everyone, for joining. You may now disconnect.